M&AInnate immunity merger raises €75mLatest NewsForbion has spearheaded a €75m Series A financing in Norwegian biotech Calluna Pharma. The clinical-stage company resulted from the merger of Oxitope Pharma and Arxx Therapeutics. Read more 24 January 2024 https://european-biotechnology.com/wp-content/uploads/2024/04/calluna-pipeline.png 899 1598 Uta Mommert /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Uta Mommert2024-01-24 09:00:002024-07-16 17:09:46Innate immunity merger raises €75m